Sana Biotechnology (SANA) Expected to Announce Quarterly Earnings on Monday

Sana Biotechnology (NASDAQ:SANA) will likely be releasing its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect Sana Biotechnology to post earnings of ($0.12) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 3:00 PM ET.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.03). On average, analysts expect Sana Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sana Biotechnology Price Performance

Shares of Sana Biotechnology stock opened at $3.15 on Monday. The stock has a market capitalization of $840.64 million, a P/E ratio of -3.25 and a beta of 1.96. The business has a 50 day simple moving average of $4.25 and a two-hundred day simple moving average of $4.14. Sana Biotechnology has a 12 month low of $1.26 and a 12 month high of $6.55.

Hedge Funds Weigh In On Sana Biotechnology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SANA. Balyasny Asset Management L.P. purchased a new stake in Sana Biotechnology in the 4th quarter valued at $6,834,000. Vanguard Group Inc. raised its holdings in shares of Sana Biotechnology by 19.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after acquiring an additional 1,517,474 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Sana Biotechnology by 180.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock valued at $7,581,000 after acquiring an additional 1,375,029 shares during the last quarter. State Street Corp boosted its position in shares of Sana Biotechnology by 20.6% during the 4th quarter. State Street Corp now owns 8,054,841 shares of the company’s stock valued at $32,783,000 after acquiring an additional 1,374,300 shares during the last quarter. Finally, Integral Health Asset Management LLC grew its holdings in shares of Sana Biotechnology by 50.0% in the fourth quarter. Integral Health Asset Management LLC now owns 3,000,000 shares of the company’s stock valued at $12,210,000 after purchasing an additional 1,000,000 shares during the period. Institutional investors and hedge funds own 88.23% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on SANA. Zacks Research cut Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. Bank of America raised their price objective on Sana Biotechnology from $6.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. HC Wainwright lowered their target price on shares of Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, March 4th. Wall Street Zen lowered shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sana Biotechnology in a research report on Monday, December 29th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Sana Biotechnology has a consensus rating of “Moderate Buy” and an average target price of $7.83.

Key Headlines Impacting Sana Biotechnology

Here are the key news stories impacting Sana Biotechnology this week:

• Positive Sentiment: HC Wainwright retained a “Buy” rating and a $7.00 price target on SANA even as it trimmed estimates — that continued institutional support can limit downside and suggests upside potential if execution improves. MarketBeat SANA
• Neutral Sentiment: Sana presented at the TD Cowen 46th Annual Health Care Conference (transcript available). Conference appearances increase management visibility to investors; the stock reaction will depend on any new data or timeline updates disclosed in the talk. TD Cowen Presentation Transcript
• Negative Sentiment: HC Wainwright cut EPS estimates across multiple quarters and out years (Q1–Q4 2026 and FY2026–2030 were revised lower), signaling slower expected progress or higher near-term spend — these reductions pressure the stock by lowering near- and medium-term earnings visibility. MarketBeat SANA (HC Wainwright notes)
• Negative Sentiment: Zacks downgraded SANA from “strong-buy” to “hold,” removing a strong buy-side endorsement and likely contributing to selling pressure from retail/quant strategies that track analyst momentum. Zacks TickerReport
• Negative Sentiment: Sana recently reported an EPS miss for the quarter (reported March 3), which combined with the analyst downgrades increases near-term uncertainty around execution and cash runway — a key concern for biotech investors. MarketBeat SANA (earnings)
• Negative Sentiment: A TipRanks piece highlights a newly disclosed risk tied to AI adoption (data, compliance, reputational risks). While not an immediate earnings driver, rising compliance risk can raise operating costs or distract management if issues emerge. TipRanks: AI Risk

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.